<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">ACR</journal-id>
         <journal-id journal-id-type="hwp">spacr</journal-id>
         <journal-title>Acta Radiologica</journal-title>
         <issn pub-type="ppub">0284-1851</issn>
         <issn pub-type="epub">1600-0455</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage UK: London, England</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0284185113475441</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0284185113475441</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Interventional radiology</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes</article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>Byung Kwan</given-names>
               </name>
               <xref ref-type="aff" rid="af1">1</xref>
               <xref ref-type="corresp" rid="cor1"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>Chan Kyo</given-names>
               </name>
               <xref ref-type="aff" rid="af1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>Sung Yoon</given-names>
               </name>
               <xref ref-type="aff" rid="af1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Shen</surname>
                  <given-names>Shu-Huei</given-names>
               </name>
               <xref ref-type="aff" rid="af2">2</xref>
            </contrib>
         </contrib-group>
         <aff id="af1">
            <label>1</label>
            <institution xlink:type="simple">The Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <addr-line>Seoul</addr-line>, <country>Korea</country>
         </aff>
         <aff id="af2">
            <label>2</label>
            <institution xlink:type="simple">The Department of Radiology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan</country>
         </aff>
         <author-notes>
            <corresp id="cor1">Correspondence to: Byung Kwan Park. Email: <email xlink:type="simple">rapark@skku.edu</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>5</month>
            <year>2013</year>
         </pub-date>
         <volume>54</volume>
         <issue>4</issue>
         <fpage>418</fpage>
         <lpage>427</lpage>
         <history>
            <date date-type="received">
               <day>16</day>
               <month>4</month>
               <year>2012</year>
            </date>
            <date date-type="accepted">
               <day>24</day>
               <month>11</month>
               <year>2012</year>
            </date>
         </history>
         <permissions>
            <copyright-statement>© 2013 The Foundation Acta Radiologica</copyright-statement>
            <copyright-year>2013</copyright-year>
            <copyright-holder content-type="sage">The Foundation Acta Radiologica</copyright-holder>
         </permissions>
         <abstract>
            <p>Renal cell carcinoma (RCC) in patients with von Hippel Lindau (VHL) disease tends to be multifocal, bilateral, and recur or develop new tumors after removal. These characteristics make treating hereditary RCCs difficult for urologists or radiologists compared to treating a sporadic RCC. Radiofrequency ablation (RFA) is a minimally-invasive treatment for small hereditary RCCs associated with a low complication rate and a minimal decrease in renal function.</p>
            <p>No RFA guidelines have been established about what to treat and when and how to ablate RCCs in patients with VHL disease. Besides, reports on complications and treatment outcomes in this patient group are rare. The purpose of this review is to discuss the indications, techniques, complications, and outcomes of RFA in treating RCC in patients with VHL disease.</p>
         </abstract>
         <kwd-group>
            <title>Keywords</title>
            <kwd>Radiofrequency ablation</kwd>
            <kwd>renal cell carcinoma</kwd>
            <kwd>von Hippel Lindau disease</kwd>
            <kwd>complication</kwd>
            <kwd>outcome</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1">
         <title/>
         <p>Patients with von Hippel Lindau (VHL) disease often present with renal cell carcinomas (RCCs) or cysts in the kidney. RCCs in these patients are characterized by multiplicity and bilaterality, and tendency to recur (<xref ref-type="bibr" rid="AR-475441C1">1</xref>–<xref ref-type="bibr" rid="AR-475441C3">3</xref>). Nephron-sparing surgery (NSS) has been the gold standard for treating hereditary RCCs as well as sporadic RCCs. However, repeated surgical treatment of recurrent RCCs in patients with VHL disease may be difficult to perform due to postoperative fibrosis and high postoperative morbidity or mortality (<xref ref-type="bibr" rid="AR-475441C4">4</xref>). In addition, even NSS may reduce renal function due to significant tissue loss (<xref ref-type="bibr" rid="AR-475441C5">5</xref>, <xref ref-type="bibr" rid="AR-475441C6">6</xref>).</p>
         <p>Management of hereditary RCCs should involve multidisciplinary discussion between urologists and radiologists to choose the appropriate treatment options, including surgery, thermal ablation, or a combination of surgery and thermal ablation for each VHL patient. No consensus has been established about how to treat hereditary RCC. Generally, surgery is recommended for large RCCs (&gt;4 cm) and thermal ablation, for small RCCs (≤4 cm). Thermal ablation, however, may be performed even for large RCCs when surgery is poorly indicated.</p>
         <p>Recently, percutaneous radiofrequency ablation (RFA) has become common for RCCs in patients with VHL disease for two reasons (<xref ref-type="bibr" rid="AR-475441C7">7</xref>–<xref ref-type="bibr" rid="AR-475441C10">10</xref>). One reason is that RFA can be used repeatedly to treat RCCs in contrast to surgery. The other reason is that RFA does not decrease renal function as much as NSS (<xref ref-type="bibr" rid="AR-475441C11">11</xref>). As a result, RFA is recommended as first-line treatment for small hereditary RCCs.</p>
         <p>Percutaneous RFA of RCCs, however, may be challenging in patients with VHL disease. While small sporadic RCCs can be treated in one or two RFA sessions, hereditary RCCs in patient with VHL disease may need repeat treatments throughout life. Hereditary RCCs can occur anywhere in the kidney and are sometimes located in close proximity to critical organs, such as the bowel, ureter, and major vessels. Other organs such as adrenal glands, pancreas, and spleen, should be protected from heat injury to prevent unexpected complications during RFA. Special prevention techniques may be required to prevent serious complications resulting from injury to adjacent organs. There are no RFA guidelines available describing which RCCs to be ablated and when, and how to ablate RCCs in patients with VHL disease. The purpose of this review is to discuss the RFA indications, techniques, complications, and outcomes in treating RCCs in patients with VHL disease.</p>
      </sec>
      <sec id="s2">
         <title>RFA indications</title>
         <sec id="s2a">
            <title>What to ablate</title>
            <p>RFA is indicated to treat cystic or solid RCCs occurring in patients with VHL disease because this thermal ablation is useful in treating cystic as well as solid RCCs (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C12">12</xref>). Cystic RCCs require shorter ablation duration and decrease in size more rapidly following RFA than RCCs of the same size (<xref ref-type="bibr" rid="AR-475441C12">12</xref>). Why cystic RCCs respond to RFA, however, remains unclear. Theoretically, cystic RCCs have a lower cancer cell volume than solid RCCs of the same size, which may account for faster ablation and more rapid size decrease of cystic RCCs (Fig. <xref ref-type="fig" rid="AR-475441F1">1</xref>). RF electrical current tends to travel farther in fluid than solid tissue, thus a wet tip RF electrode creates a larger ablation area than a non-wet tip RF electrode (<xref ref-type="bibr" rid="AR-475441C13">13</xref>, <xref ref-type="bibr" rid="AR-475441C14">14</xref>). Venkatesan <italic>et al.</italic> reported that a large cystic RCC (≥3 cm) may be difficult to heat (<xref ref-type="bibr" rid="AR-475441C15">15</xref>). Complete ablation, however, was more easily achieved in a large cystic RCC (&gt;3 cm) than a large solid RCC (&gt;3 cm) (Figs. <xref ref-type="fig" rid="AR-475441F1">1</xref> and <xref ref-type="fig" rid="AR-475441F2">2</xref>) (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C12">12</xref>). Therefore, RFA should be considered for cystic RCCs in patients who are poor candidates to surgery. Intuitively, cancer could be seeded after a cystic mass is perforated. However, this complication is extremely rare, even in percutaneous cysticic mass biopsy in which a cystic mass is ruptured and cystic fluid leaks (<xref ref-type="bibr" rid="AR-475441C16">16</xref>, <xref ref-type="bibr" rid="AR-475441C17">17</xref>). Furthermore, cyst rupture and fluid leakage barely result in cancer seeding because cystic RCC cells are killed by boiling cystic fluid during RFA.
<fig id="AR-475441F1" position="float">
                  <label>Fig. 1</label>
                  <caption>
                     <p>Percutaneous RFA of a large cystic RCC in a 36-year-old man with VHL disease. (a) An axial contrast-enhanced pre-ablation CT image shows two Bosniak category III cystic masses (open arrows) measuring 2.7 cm and 5.9 cm in the right and left kidneys, respectively. Two solid masses (solid arrows) measure 4.7 cm and 3.0 cm in the right and left kidneys, respectively. (b) An axial contrast-enhanced CT image shows that the cystic masses (open arrows) have decreased more rapidly than the solid masses (solid arrows) 27 months after the previous RFA. A new Bosniak category IIF cystic mass (arrowhead) is detected in the left kidney</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig1.tif" xlink:type="simple"/>
               </fig>
               <fig id="AR-475441F2" position="float">
                  <label>Fig. 2</label>
                  <caption>
                     <p>A 24-year-old man with von Hippel Lindau disease. (a) An axial contrast-enhanced pre-ablation CT image shows a cystic renal tumor (arrow) that contains solid components (arrowheads), suggesting of a Bosniak IV cystic mass. The lesion measures 6 cm in maximum diameter. The tumor was treated with percutaneous radiofrequency ablation in one session. (b) An axial contrast-enhanced CT image obtained four months following the ablation shows no enhancement within the cystic mass (arrow). The tumor decreases 5 cm in maximum diameter</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig2.tif" xlink:type="simple"/>
               </fig>
            </p>
            <p>A Bosniak III or IV cystic mass is considered a cystic RCC in patients with VHL disease (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C12">12</xref>). A significant number of Bosniak III cystic masses are diagnosed postoperatively as benign lesions in patients who have no history of hereditary RCC (<xref ref-type="bibr" rid="AR-475441C18">18</xref>). However, 21% of renal cysts in VHL disease have microscopic cancer foci, which appear benign on imaging studies (<xref ref-type="bibr" rid="AR-475441C19">19</xref>, <xref ref-type="bibr" rid="AR-475441C20">20</xref>). Pre-ablation biopsy of Bosniak III or IV cystic masses does not change the treatment plan regardless of pathologic results (<xref ref-type="bibr" rid="AR-475441C12">12</xref>). If a biopsy result is positive for malignancy, it merely confirms the need for surgery. If a biopsy result is negative for malignancy, it cannot exclude the possibility of false-negative resulting from sampling error.</p>
            <p>If one of multiple solid masses in VHL disease is histologically diagnosed as RCC, the other solid masses are considered as RCCs because biopsies cannot be performed for all renal masses (<xref ref-type="bibr" rid="AR-475441C21">21</xref>). A new solid mass in VHL disease should be considered as a RCC without histologic proof if the imaging features of the lesion are similar to those of a previous RCC that is histologically confirmed by biopsy or surgery (Fig. <xref ref-type="fig" rid="AR-475441F3">3</xref>) (<xref ref-type="bibr" rid="AR-475441C9">9</xref>). If a solid renal mass has no fat tissue in a patient with VHL disease that is clinically or genetically confirmed, it strongly suggests RCC in contrast to that in a patient with tuberous sclerosis in whom a significant number of solid renal masses are pathologically diagnosed as angiomyolipoma even if the lesions have no fat tissue on CT or MRI (<xref ref-type="bibr" rid="AR-475441C22">22</xref>).
<fig id="AR-475441F3" position="float">
                  <label>Fig. 3</label>
                  <caption>
                     <p>Percutaneous RFA of a large solid RCC in a 54-year-old man with VHL disease. (a) An axial contrast-enhanced pre-ablation CT image shows a solid mass (arrows) measuring 5.3 cm in size. (b) An axial contrast-enhanced CT image shows a residual lesion (arrowheads) within the tumor following the two sessions of radiofrequency ablation. The unenhanced area (asterisk) indicates ablation zone. The patient underwent a left radical nephrectomy that histologically confirmed clear cell type RCC. (c) An axial contrast-enhanced CT image shows a new solid tumor (arrow) that is homogenously well-enhanced. The lesion is considered a RCC because of the CT features similar to those of the previously removed RCC</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig3.tif" xlink:type="simple"/>
               </fig>
            </p>
         </sec>
         <sec id="s2b">
            <title>When to ablate</title>
            <p>RFA is generally indicated in RCCs &gt;1 cm in diameter. Thermal ablation is not recommended for renal masses ≤1 cm for several reasons. First, a renal mass ≤1 cm is hard to characterize even using the state-of-the-art imaging techniques (<xref ref-type="bibr" rid="AR-475441C17">17</xref>). Pseudoenhancement is common in small renal lesions on multidetector row CT scanners so the possibility of a false-positive diagnosis appear (<xref ref-type="bibr" rid="AR-475441C23">23</xref>, <xref ref-type="bibr" rid="AR-475441C24">24</xref>). Second, renal masses ≤1 cm are difficult to target. Incorrect targeting may bring up a false-negative result or unnecessary tissue injury. Third, RCCs ≤1 cm seldom metastasize (<xref ref-type="bibr" rid="AR-475441C25">25</xref>). Therefore, simple observation is considered the management of choice for small renal masses measuring ≤1 cm (<xref ref-type="bibr" rid="AR-475441C17">17</xref>).</p>
            <p>The ideal size of a hereditary RCC ablated with RFA should be between 1 cm and 3 cm. Generally, a 5 mm tumor margin is necessary for complete ablation by RFA. For a 1 cm spherical parenchymal RCC treated with RFA, the tumor margin volume (3.5 cm<sup>3</sup>) is seven times larger than the tumor volume (0.5 cm<sup>3</sup>) (Table <xref ref-type="table" rid="AR-475441TB1">1</xref>) (<xref ref-type="bibr" rid="AR-475441C26">26</xref>). The tumor margin volumes of 2–4 cm spherical parenchymal RCCs range approximately 10–30 cm<sup>3</sup>. In a case with multiple spherical parenchymal RCCs arising from a 240 cm<sup>3</sup> single kidney, theoretically 12 RCCs measuring 2 cm in diameter can be ablated while only four RCCs measuring 4 cm in diameter can be ablated before more than half of the initial kidney volume is destroyed. Therefore, the ideal size of a hereditary RCC for RFA is 1–3 cm in size. A cystic or solid RCC measuring ≤1 cm should be observed until it exceeds 1 cm in diameter. A RCC &gt;3 cm is more likely to have a residual or recurrent tumor than that of ≤3 cm (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C21">21</xref>, <xref ref-type="bibr" rid="AR-475441C27">27</xref>). Follow-up imaging examinations are recommended at regular intervals to early detect recurrent RCCs or local tumor progression in patients with VHL disease. Although optimal time intervals for follow-up imaging examination are not established, CT or MR examination should be performed at least once a year.
<table-wrap id="AR-475441TB1" position="float">
                  <label>Table 1</label>
                  <caption>
                     <p>Comparison of RFA and cryoablation in terms of tumor margin</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                     <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                        <col align="left" span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th colspan="1" rowspan="1"/>
                           <th colspan="1" rowspan="1"/>
                           <th align="left" colspan="2" rowspan="1">Volume of tumor <break/>margin (cm<sup>3</sup>)</th>
                           <th align="left" colspan="2" rowspan="1">Volume of <break/>RCC + tumor <break/>margin (cm<sup>3</sup>)</th>
                        </tr>
                        <tr>
                           <th align="left" colspan="1" rowspan="1">Diameter <break/>of RCC <break/>(cm)</th>
                           <th align="left" colspan="1" rowspan="1">Volume <break/>of RCC <break/>(cm<sup>3</sup>)</th>
                           <th align="left" colspan="1" rowspan="1">RFA</th>
                           <th align="left" colspan="1" rowspan="1">Cryoablation</th>
                           <th align="left" colspan="1" rowspan="1">RFA</th>
                           <th align="left" colspan="1" rowspan="1">Cryoablation</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td colspan="1" rowspan="1">1</td>
                           <td colspan="1" rowspan="1">0.5</td>
                           <td colspan="1" rowspan="1">3.5</td>
                           <td colspan="1" rowspan="1">13</td>
                           <td colspan="1" rowspan="1">4</td>
                           <td colspan="1" rowspan="1">13.5</td>
                        </tr>
                        <tr>
                           <td colspan="1" rowspan="1">2</td>
                           <td colspan="1" rowspan="1">4</td>
                           <td colspan="1" rowspan="1">9.5</td>
                           <td colspan="1" rowspan="1">28</td>
                           <td colspan="1" rowspan="1">13.5</td>
                           <td colspan="1" rowspan="1">32</td>
                        </tr>
                        <tr>
                           <td colspan="1" rowspan="1">3</td>
                           <td colspan="1" rowspan="1">13.5</td>
                           <td colspan="1" rowspan="1">18.5</td>
                           <td colspan="1" rowspan="1">49</td>
                           <td colspan="1" rowspan="1">32</td>
                           <td colspan="1" rowspan="1">62.5</td>
                        </tr>
                        <tr>
                           <td colspan="1" rowspan="1">4</td>
                           <td colspan="1" rowspan="1">32</td>
                           <td colspan="1" rowspan="1">30.5</td>
                           <td colspan="1" rowspan="1">76</td>
                           <td colspan="1" rowspan="1">62.5</td>
                           <td colspan="1" rowspan="1">108</td>
                        </tr>
                     </tbody>
                  </table>
                  <table-wrap-foot>
                     <fn>
                        <p>There are two hypotheses for Table 1. One is that a RCC is completely spherical parenchymal tumor. The other is that 4π/3 is regarded as 4. The volume of a RCC is calculated from 4π × r<sup>3</sup>/3 in which “π” and “r” indicates the ratio of the circumference of a circle to its diameter and the radius of the RCC, respectively. The volume of tumor margin is calculated according to the premise that RFA and cryoablation require 0.5 and 1.0 cm tumor margin around the lesion, respectively. Therefore, the ablation volume minus the tumor volume is the volume of the tumor margin</p>
                     </fn>
                     <fn>
                        <p>RCC, renal cell carcinoma; RFA, radiofrequency ablation</p>
                     </fn>
                  </table-wrap-foot>
               </table-wrap>
            </p>
            <p>Generally, surgery is not indicated for a RCC &lt;3 cm in patients with VHL disease because these RCCs are low grade and not likely to metastasize (<xref ref-type="bibr" rid="AR-475441C3">3</xref>, <xref ref-type="bibr" rid="AR-475441C28">28</xref>). However, RCCs ≥3 cm needs sacrifice of more normal renal tissue at the tumor margin, resulting in more reduction of renal function. Furthermore, RCCs &gt;3 cm in patients who are poor candidates for surgery are difficult to treat with RFA alone because of frequent local tumor progression, consequently multiple RFA sessions are required for complete ablation (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C21">21</xref>, <xref ref-type="bibr" rid="AR-475441C27">27</xref>) and renal function may be further impaired. Therefore, hereditary RCCs (&gt;1 cm) that are detected on imaging examinations should be treated with RFA before these tumors exceed 3 cm in diameter.</p>
         </sec>
      </sec>
      <sec id="s3">
         <title>RFA techniques</title>
         <sec id="s3a">
            <title>RFA <italic>versus</italic> cryoablation</title>
            <p>Cryoablation has several advantages over RFA. Cryoablation is less painful, (<xref ref-type="bibr" rid="AR-475441C29">29</xref>) the ablation area is depicted more clearly than RFA under CT guidance (<xref ref-type="bibr" rid="AR-475441C30">30</xref>), cryoablation causes less thermal injury to the urothelium, (<xref ref-type="bibr" rid="AR-475441C31">31</xref>) and cryoablation can ablate larger tumors than RFA. Despite these disadvantages of RFA over cryoablation, it seems to be a better treatment option for hereditary RCC than cryoablation with respect to technical feasibility and renal function change. Targeting a tumor is easier with RFA because a single RF applicator alone can treat a 2 cm RCC while cryoablation requires three applicators (<xref ref-type="bibr" rid="AR-475441C32">32</xref>). Using multiple applicators to target a central or parenchymal RCC can result in mechanical injury to the sinus vessels or urinary tracts. Generally, the tumor margin for cryoablation is larger than that for RFA and it requires 10 mm for complete ablation (<xref ref-type="bibr" rid="AR-475441C32">32</xref>). RFA and cryoablation should ablate about 10 cm<sup>3</sup> and 30 cm<sup>3</sup>, respectively, of normal renal tissue to treat a 2-cm spherical parenchymal RCC (Table <xref ref-type="table" rid="AR-475441TB1">1</xref>). For example, in treating multiple spherical parenchymal RCCs in a 240 cm<sup>3</sup> single kidney measuring, RFA can ablate 12 2-cm RCCs while cryoablation can ablate only four 2-cm RCCs before more than half of the initial renal volume is destroyed. Microwave ablation has been used to treat a sporadic RCC, but it has not been reported in treating hereditary RCC. Microwave ablation creates a larger ablation area than RFA due to a lower heat sink effect.</p>
            <p>Under CT guidance, the radiation dose incurred during RFA is much less than that incurred during cryoablation. RFA procedures consist of planning, targeting, and post-ablation survey phases while cryoablation procedure requires monitoring phase additionally. Furthermore, since multiple applicators are used to target a tumor, more CT scans may be needed during the targeting phase of cryoablation, consequently exposing patients to more radiation dose.</p>
         </sec>
         <sec id="s3b">
            <title>Guiding modalities</title>
            <p>Ultrasonography (US) has several advantages over CT for guiding thermal ablation, including real-time imaging, no radiation hazard, and no use of iodine contrast material. CT, however, provides better guidance than US for treating RCCs with RFA (<xref ref-type="bibr" rid="AR-475441C33">33</xref>). Under US guidance, RFA produces hyper-echoic bubbles with strong posterior shadowing that obscure the posterior margin of the tumor (<xref ref-type="bibr" rid="AR-475441C33">33</xref>). A poor depicted RCC may hamper complete ablation of RCC under US guidance (Fig. <xref ref-type="fig" rid="AR-475441F4">4</xref>). A residual lesion is impossible to identify during an US-guided RFA procedure. Recently, US contrast agents have been reported to be useful in depicting residual lesions during and after RFA (<xref ref-type="bibr" rid="AR-475441C34">34</xref>, <xref ref-type="bibr" rid="AR-475441C35">35</xref>). Even with contrast-enhanced US, however, the entire margin of a renal tumor cannot be visualized if it is adjacent to bone, bowel, or lung. Furthermore, contrast-enhanced US results in more false-positive lesions than contrast-enhanced CT (<xref ref-type="bibr" rid="AR-475441C34">34</xref>). Residual or recurrent lesions are more frequent following US-guided RFA than CT-guided RFA due to incomplete ablation of tumor margin (<xref ref-type="bibr" rid="AR-475441C33">33</xref>). RFA electrodes are not commonly used under MR guidance because the electric current disturbs the magnetic field and MR artifacts distort MR images. A few recent studies have reported that MR-guided RFA of RCC is promising in treating a RCC (<xref ref-type="bibr" rid="AR-475441C36">36</xref>, <xref ref-type="bibr" rid="AR-475441C37">37</xref>). MR-compatible RF electrodes are not widely available.
<fig id="AR-475441F4" position="float">
                  <label>Fig. 4</label>
                  <caption>
                     <p>US-guided RFA of a solid RCC in a 39-year-old woman with VHL disease. (a) A longitudinal pre-ablation US image (left) shows an ill-defined hyperechoic solid RCC (solid arrows) in the right kidney. The longitudinal US image (right) shows hyperechoic bubbles (solid arrowheads) resulting in strong posterior shadowing (open arrowheads) during RFA. Open arrows indicate an RFA electrode targeting the tumor. (b) An axial contrast-enhanced pre-ablation CT image (left) shows a solid RCC (arrow) with strong enhancement. The contrast-enhanced post-ablation CT image (right) shows a marginal tumor enhancement (solid arrowhead) suggesting a residual lesion. Open arrowheads indicate subcapsular hematoma following the US-guided RFA</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig4.tif" xlink:type="simple"/>
               </fig>
            </p>
            <p>In contrast to US and MR, CT guidance results in a considerable radiation dose because multiple RFA sessions are required to treat recurrent RCCs in patients with VHL disease. Generally, the radiation dose can be reduced with low mAs, low kVp, narrow scan range, and fewer scans (<xref ref-type="bibr" rid="AR-475441C32">32</xref>). Combining US with CT may reduce the radiation dose incurred during targeting a tumor (<xref ref-type="bibr" rid="AR-475441C38">38</xref>). The navigation system also may allow for less radiation dose by enhancing the confidence for lesion targeting (<xref ref-type="bibr" rid="AR-475441C39">39</xref>, <xref ref-type="bibr" rid="AR-475441C40">40</xref>).</p>
            <p>Unenhanced CT is usually performed during RFA procedure. Contrast enhancement, however, is sometimes necessary to determine if the ablation zone is large enough to cover the entire tumor margin. RFA of a parenchymal RCC frequently requires contrast-enhanced CT because the parenchymal RCC is not clearly demarcated on unenhanced CT images.</p>
         </sec>
      </sec>
      <sec id="s4">
         <title>Type of anesthesia</title>
         <p>Monitored anesthesia care is generally used for conscious sedation during RFA of sporadic RCCs. However, the use of general anesthesia is not uncommon in treating hereditary RCCs. General anesthesia is recommended when monitored anesthesia care alone cannot control pain, when two or more RCCs are treated in a session, and when a large RCC takes so long time that a patient may not endure the entire procedure. RFA of a single small RCC is usually tolerable in a patient with VHL that occurs in young ages. However, RFA of a large RCC or multiple RCCs requires multiple targeting and repeated ablation procedures. Subsequently, patients are so exhausted that they cannot cooperate well. The number of CT scan may increase because targeting a tumor is often difficult in these situations. In contrast to monitored anesthesia care, general anesthesia makes a patient breathe at a regular rate and helps tumor targeting. The ventilator should be turned off during the CT scan in order to remove artifacts due to respiratory motion.</p>
      </sec>
      <sec id="s5">
         <title>Prevention methods</title>
         <p>To protect neighboring organs, several prevention methods are performed before or during RFA (<xref ref-type="bibr" rid="AR-475441C41">41</xref>). Non-invasive prevention methods include changing patient's position and levering an applicator (Fig. <xref ref-type="fig" rid="AR-475441F5">5</xref>) (<xref ref-type="bibr" rid="AR-475441C41">41</xref>–<xref ref-type="bibr" rid="AR-475441C43">43</xref>). Invasive prevention methods include hydrodissection, pneumodissection, and balloon interposition (<xref ref-type="bibr" rid="AR-475441C44">44</xref>, <xref ref-type="bibr" rid="AR-475441C45">45</xref>). Hydrodissection is most commonly used to displace bowel from the tumor (Fig. <xref ref-type="fig" rid="AR-475441F6">6</xref>). Non-invasive prevention methods are easy and work well enough that hydrodissection is not necessary in most cases. Therefore, for RCCs close to the bowel, the first step is to change the patient's position. If a position change does not work, the applicator can be levered to displace the tumor from the bowel. If neither of these methods works, hydrodissection can be used.
<fig id="AR-475441F5" position="float">
               <label>Fig. 5</label>
               <caption>
                  <p>Levering an RF electrode in a 24-year-old man with VHL disease. (a) An axial contrast-enhanced CT image (left) shows an RF electrode (arrowheads) targeting a tumor which is in close proximity to the transverse colon (C). The tumor-to-bowel distance is &lt;5 mm. The axial contrast-enhanced CT image (right) shows the tumor-to-bowel distance (both-side arrow) increasing &gt;10 mm by means of levering the RF electrode. Asterisk indicates an incidental hematoma around a right rib. (b) An axial contrast-enhanced pre-ablation CT image (left) shows an RCC (arrow) in proximity to transeverse colon (C). The tumor-to-bowel distance is &lt;5 mm. The axial contrast-enhanced post-ablation CT image (right) shows the complete ablation of the RCC (arrow) without thermal injury to the colon wall (arrowhead)</p>
               </caption>
               <graphic position="float" xlink:href="10.1177_0284185113475441-fig5.tif" xlink:type="simple"/>
            </fig>
            <fig id="AR-475441F6" position="float">
               <label>Fig. 6</label>
               <caption>
                  <p>Hydrodissection in a 29-year-old man with VHL disease. An axial contrast-enhanced pre-ablation CT image (left) shows a right RCC (arrow) in proximity to transverse colon (C) and second portion duodenum (D). The axial contrast-enhanced CT image (right) shows the RCC (arrow) displaced from the bowels &gt;5 mm by means of hydrodissection (arrowheads)</p>
               </caption>
               <graphic position="float" xlink:href="10.1177_0284185113475441-fig6.tif" xlink:type="simple"/>
            </fig>
         </p>
         <p>In our experience, hydrodissection might be better after targeting than before targeting, which does not agree with the general consensus among interventional radiologists. When an applicator is placed in a tumor, the lesion location can be changed because the applicator frequently displaces or rotates the kidney (Fig. <xref ref-type="fig" rid="AR-475441F7">7</xref>). Therefore, if possible, we often target a tumor first even if the lesion is located close to the bowel on pre-ablation CT images. The tumor-to-bowel distance may also increase &gt;5 mm because of hematoma occurring during targeting. This hematoma is one of frequent complications that occur during targeting procedure for RFA or biopsy, but this complication rarely results in cancer seeding (<xref ref-type="bibr" rid="AR-475441C46">46</xref>, <xref ref-type="bibr" rid="AR-475441C47">47</xref>).
<fig id="AR-475441F7" position="float">
               <label>Fig. 7</label>
               <caption>
                  <p>No hydrodissection for RFA of RCC in a 38-year-old man with VHL disease. An axial contrast-enhanced pre-ablation CT image (left) shows a left RCC (arrow) in proximity to adjacent small bowel (arrowhead). The axial unenhanced CT image (middle) shows the RCC (arrow) displaced from the bowel (arrowhead) &gt;5 mm immediately after targeting. The post-ablation axial contrast-enhanced CT image (right) shows not only complete ablation of the tumor (arrow) but also no injury to the bowel (arrowhead)</p>
               </caption>
               <graphic position="float" xlink:href="10.1177_0284185113475441-fig7.tif" xlink:type="simple"/>
            </fig>
         </p>
         <p>Hydrodissection before targeting increases the skin-to-tumor distance and subsequently a tumor may become more difficult to target (<xref ref-type="bibr" rid="AR-475441C48">48</xref>). Additionally, the kidney with a RCC often becomes more movable, making it difficult for the operator to place the applicator where an operator wants to ablate. If hydrodissection is unnecessary after targeting, the radiation dose and cost are less than if hydrodissection is performed before targeting.</p>
         <p>To prevent ureteral injury during RFA, retrograde infusion of cool saline into the collecting system is generally recommended (<xref ref-type="bibr" rid="AR-475441C49">49</xref>, <xref ref-type="bibr" rid="AR-475441C50">50</xref>). In our experience, ureteral catheterization and intravenous administration of contrast material have potential to prevent ureteral injury (<xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C41">41</xref>) (Fig. <xref ref-type="fig" rid="AR-475441F8">8</xref>). Iodine contrast material may have a diuretic effect, subsequently resulting in a heat sink effect that decreases heat energy delivered to the ureter. Since an indwelling ureteral catheter is left for at least 4 weeks, it may also prevent delayed ureteral stricture (<xref ref-type="bibr" rid="AR-475441C51">51</xref>). However, this prevention method requires further investigation.
<fig id="AR-475441F8" position="float">
               <label>Fig. 8</label>
               <caption>
                  <p>Internal ureter catheterization in a 24-year-old man with VHL disease. (a) A pre-ablation CT image shows a Bosniak IV cystic mass (arrow) abutting left ureteropelvic junction (solid arrowhead). Internal catheter was introduced into the left upper urinary tract to prevent thermal injury. (b) A post-ablation CT image obtained 1 month after RFA shows not only size reduction and complete ablation of the cystic RCC but also no thermal injury to the ureteropelvic junction (solid arrowhead) in which a catheter still exist. The catheter was removed immediately after no thermal injury was confirmed. An open arrowhead indicates an upper tip of the catheter</p>
               </caption>
               <graphic position="float" xlink:href="10.1177_0284185113475441-fig8.tif" xlink:type="simple"/>
            </fig>
         </p>
      </sec>
      <sec id="s6">
         <title>RFA complications</title>
         <p>Complications related with RFA can be classified as major or minor complications (<xref ref-type="bibr" rid="AR-475441C41">41</xref>, <xref ref-type="bibr" rid="AR-475441C52">52</xref>). Major complications require emergent or elective treatment or possibly result in permanent sequelae or death. In contrast, minor complications spontaneously disappear without specific treatment.</p>
         <sec id="s6a">
            <title>Major complications</title>
            <p>The major complication rate of RFA for treating RCCs is 0–8% in patients with VHL disease (<xref ref-type="bibr" rid="AR-475441C7">7</xref>–<xref ref-type="bibr" rid="AR-475441C10">10</xref>). This rate is slightly lower than major complication of surgery that ranges 6–14% (<xref ref-type="bibr" rid="AR-475441C1">1</xref>, <xref ref-type="bibr" rid="AR-475441C53">53</xref>). Major complications include bowel perforation, ureteral stricture, uncontrolled bleeding, and residual or recurrent cancers (<xref ref-type="bibr" rid="AR-475441C41">41</xref>). These major complications rarely occur but cause serious problems that requires emergent or elective intervention or surgical treatment. Bowel injury is the most fatal complication because it may cause bowel perforation, abscess formation, or sepsis (Fig. <xref ref-type="fig" rid="AR-475441F9">9</xref>) (<xref ref-type="bibr" rid="AR-475441C41">41</xref>, <xref ref-type="bibr" rid="AR-475441C48">48</xref>, <xref ref-type="bibr" rid="AR-475441C54">54</xref>). The incidence of bowel injury is low because most interventional radiologists are careful to avoid it. Ureteral injury is also a serious complication that may cause permanent stricture, subsequently requiring percutaneous nephrostomy or nephrectomy (<xref ref-type="bibr" rid="AR-475441C51">51</xref>) (Fig. <xref ref-type="fig" rid="AR-475441F10">10</xref>). Uncontrolled bleeding can be caused by mechanical injury to major vessels. When an applicator traverses the renal sinus to treat a central RCC, arteriovenous fistula and urinary stricture may occur (<xref ref-type="bibr" rid="AR-475441C55">55</xref>). A residual or recurrent RCC is a major complication that can occur when a tumor or tumor margin is not sufficiently ablated (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>).
<fig id="AR-475441F9" position="float">
                  <label>Fig. 9</label>
                  <caption>
                     <p>Thermal injury to bowel in a pig model. (a) A pre-ablation CT image (left) shows an RF electrode (arrow) placed within the anterior portion of mid left kidney. Note an adjacent colonic loop (arrowheads) is closely located to the electrode. The immediate post-ablation CT image (right) shows wall thickening and enhancement of the large bowel (arrowheads) due to heat injury. An asterisk indicates the ablation zone within the anterior renal parenchyma. (b) Explo-laparotomy performed 1 week after the RFA shows the descending colon (B) severely adhered to the anterior aspect of the left kidney (K). Arrowheads indicate the adhesion between the left kidney and large bowel</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig9.tif" xlink:type="simple"/>
               </fig>
               <fig id="AR-475441F10" position="float">
                  <label>Fig. 10</label>
                  <caption>
                     <p>Ureteropelvic junction stricture in a 38-year-old woman with VHL disease. A pre-ablation CT image (left) shows an RCC (arrow) arising from the medial right lower kidney. The immediate post-ablation CT image (right) shows a thickened wall of the right ureteropelvic junction (solid arrowhead), resulting in hydronephrosis (open arrowhead). An asterisk indicates the ablated RCC</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig10.tif" xlink:type="simple"/>
               </fig>
            </p>
         </sec>
         <sec id="s6b">
            <title>Minor complications</title>
            <p>The minor complications include hematuria, hematoma, pneumothorax, and segmental infarction (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C41">41</xref>). The minor complication rate is relatively high, 58–66%. Minor complications require observation or conservative treatment, but may pose serious problems depending on the circumstances. If a pneumothorax is aggravated, despite adequate oxygen supply, percutaneous aspiration or drainage should be performed (Fig. <xref ref-type="fig" rid="AR-475441F11">11</xref>) (<xref ref-type="bibr" rid="AR-475441C56">56</xref>). If a pulmonary bulla is punctured by an applicator, tension pneumothorax may occur (<xref ref-type="bibr" rid="AR-475441C57">57</xref>). Segmental infarction and calyectasis are not problematic in patients with normal renal function but do cause renal failure in patients with marginal renal function (Fig. <xref ref-type="fig" rid="AR-475441F12">12</xref>) (<xref ref-type="bibr" rid="AR-475441C58">58</xref>). These patients may have a single kidney, chronic kidney disease, a history of repeated renal surgery, infarction, or chronic pyelonephritis. Interventional radiologists should also consider hidden major complications such as arteriovenous fistula when hematuria does not disappear spontaneously but lasts more than 3 days (<xref ref-type="bibr" rid="AR-475441C55">55</xref>).
<fig id="AR-475441F11" position="float">
                  <label>Fig. 11</label>
                  <caption>
                     <p>Pneumothorax in a 42-year-old man with VHL disease. (a) A pre-ablation CT image shows a small left RCC (arrow) contacting the pancreas tail (P). Perpendicular insertion of an RF electrode was performed because oblique access to the tumor may cause mechanical injury to the renal sinus containing major vessels and collecting system. (b) An ablation CT image shows pneumothorax (asterisk) gradually increasing despite nasal oxygen supply. An 18-guage needle (solid arrowhead) for aspiration is placed within the left pneumothorax cavity. An open arrowhead indicates an RF electrode targeting the RCC</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig11.tif" xlink:type="simple"/>
               </fig>
               <fig id="AR-475441F12" position="float">
                  <label>Fig. 12</label>
                  <caption>
                     <p>Calyectasis in a 30-year-old man with VHL disease. (a) An ablation CT shows an RF electrode (arrowheads) traversing the renal sinus to target a RCC in the anterior renal parenchyma. (b) A post-ablation CT shows an upper calyectasis (asterisk) due to infundibular stricture that may be caused by thermal injury. The patient had a history of repeated partial nephrectomies and RFA sessions prior to RFA. The estimated eGFR was 73 mL/min before RFA but was reduced to 59 mL/min after RFA</p>
                  </caption>
                  <graphic position="float" xlink:href="10.1177_0284185113475441-fig12.tif" xlink:type="simple"/>
               </fig>
            </p>
         </sec>
         <sec id="s6c">
            <title>Unavoidable complications</title>
            <p>Gradual reduction of renal function is unavoidable following RFA as well as surgery (<xref ref-type="bibr" rid="AR-475441C7">7</xref>–<xref ref-type="bibr" rid="AR-475441C9">9</xref>, <xref ref-type="bibr" rid="AR-475441C59">59</xref>). The reduction of estimated glomerular filtration rate after the last RFA session ranges from 7.6–12.8% (<xref ref-type="bibr" rid="AR-475441C7">7</xref>–<xref ref-type="bibr" rid="AR-475441C9">9</xref>). As described above, normal renal tissue should be ablated as tumor margin to prevent local tumor progression. As RCC becomes larger, tumor margin volume being ablated increases. As the number of RFA session increases, residual renal function decreases. If more normal renal tissue is included for tumor margin, the likelihood of residual or recurrent tumors decreases but so does renal function. The volume of tumor margin ablated may differ depending on tumor location. Theoretically, a parenchymal RCC requires a larger tumor margin than an exophytic or central RCC of the same size. A central RCC seems to be equivalent to an exophytic RCC in terms of tumor margin volume but the former is more susceptible to segmental infarction because a small branch of a renal artery can be coagulated during RFA (<xref ref-type="bibr" rid="AR-475441C58">58</xref>). Therefore, a pre-RFA plan should be carefully set up, not only to eradicate a RCC but also to preserve renal function. Recently, studies have reported that percutaneous RFA or cryoablation of a sporadic RCC did not significantly reduce renal function (<xref ref-type="bibr" rid="AR-475441C60">60</xref>–<xref ref-type="bibr" rid="AR-475441C64">64</xref>). Rather, the residual renal function after ablation depends on the location (exophytic, parenchymal, and central), size, and number of RCCs (<xref ref-type="bibr" rid="AR-475441C11">11</xref>, <xref ref-type="bibr" rid="AR-475441C26">26</xref>). For example, renal function will not change significantly after ablating one exophytic, small, and single RCC. However, ablating multiple, large, or parenchymal RCC will significantly reduce the renal function.</p>
            <p>Excessive radiation exposure to patients is unavoidable with CT-guided RFA. Unlike sporadic RCCs, hereditary RCCs tend to be recurrent and multifocal. Subsequently, RFA of hereditary RCCs requires more frequent RFA sessions, which exposes patients to higher radiation doses than sporadic RCCs. This increased radiation exposure may be problematic in patients with VHL disease if RCCs develop at a relatively young age. The effective dose during CT-guided RFA of RCC has not been reported but may be similar to that of CT-guided RFA of a liver tumor that measures 35.3 mSv (<xref ref-type="bibr" rid="AR-475441C65">65</xref>). CT-guided cryoablation exposes higher radiation dose than CT-guided RFA (<xref ref-type="bibr" rid="AR-475441C32">32</xref>). Therefore, interventional radiologists should adopt any possible measures to reduce radiation dose, including reducing number of CT scan, narrowing the scan range, lowering the current or voltage, and using navigation system for tumor targeting (<xref ref-type="bibr" rid="AR-475441C32">32</xref>, <xref ref-type="bibr" rid="AR-475441C39">39</xref>, <xref ref-type="bibr" rid="AR-475441C40">40</xref>).</p>
         </sec>
      </sec>
      <sec id="s7">
         <title>RFA outcomes</title>
         <p>The best approach to manage RCCs in patients with VHL disease is to remove as many RCCs as possible while preserving as much renal function as possible. RCCs in patients with VHL disease are treated surgically with the understanding that microscopic cancer cells will probably remain (<xref ref-type="bibr" rid="AR-475441C2">2</xref>). Accordingly, the local recurrence rate is high: 29–46% at 5 years and 84–85% at 10 years after surgery (<xref ref-type="bibr" rid="AR-475441C1">1</xref>, <xref ref-type="bibr" rid="AR-475441C53">53</xref>). In contrast, local tumor progression is low following RFA although there have been no comparative studies. Following RFA, however, new RCCs frequently arise in other locations within the renal parenchyma during the follow-up period. The incidence of new RCCs is 27–33% with a mean follow-up period of 23–27 months after RFA (<xref ref-type="bibr" rid="AR-475441C7">7</xref>, <xref ref-type="bibr" rid="AR-475441C9">9</xref>). For interventional radiologists, the new tumors pose the dilemma of how many times RFA should be performed. Still, whether RFA results in better long-term outcomes than surgery remains unclear. RFA has a potential to provide a longer dialysis-free period to patients with VHL disease.</p>
      </sec>
      <sec id="s8" sec-type="conclusions">
         <title>Conclusion</title>
         <p>Percutaneous RFA has many advantages over surgery for treating small RCCs in patients with VHL disease and is often used as the primary modality in these patients because the thermal ablation can repeatedly treat hereditary RCCs but also preserve renal function compared to surgery. Therefore, the quality of life in these patients undergoing RFA is expected to be better than in patients undergoing surgery.</p>
         <p>
            <bold>Conflict of interest:</bold> None.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <title>REFERENCES</title>
         <ref id="AR-475441C1">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Ploussard</surname>
                  <given-names>G</given-names>
               </name>, <name name-style="western">
                  <surname>Droupy</surname>
                  <given-names>S</given-names>
               </name>, <name name-style="western">
                  <surname>Ferlicot</surname>
                  <given-names>S</given-names>
               </name>, <etal/>
               <article-title>Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease</article-title>. <source>Urology</source>
               <year>2007</year>;<volume>70</volume>:<fpage>435</fpage>–<lpage>9</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C2">
            <label>2</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Reed</surname>
                  <given-names>AB</given-names>
               </name>, <name name-style="western">
                  <surname>Parekh</surname>
                  <given-names>DJ</given-names>
               </name>. <article-title>Surgical management of von Hippel-Lindau disease: urologic considerations</article-title>. <source>Surg Oncol Clin N Am</source>
               <year>2009</year>;<volume>18</volume>:<fpage>157</fpage>–<lpage>74</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C3">
            <label>3</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Shuin</surname>
                  <given-names>T</given-names>
               </name>, <name name-style="western">
                  <surname>Yamasaki</surname>
                  <given-names>I</given-names>
               </name>, <name name-style="western">
                  <surname>Tamura</surname>
                  <given-names>K</given-names>
               </name>, <etal/>
               <article-title>Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment</article-title>. <source>Jpn J Clin Oncol</source>
               <year>2006</year>;<volume>36</volume>:<fpage>337</fpage>–<lpage>43</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C4">
            <label>4</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Bratslavsky</surname>
                  <given-names>G</given-names>
               </name>, <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>JJ</given-names>
               </name>, <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>AD</given-names>
               </name>, <etal/>
               <article-title>Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes</article-title>. <source>J Urol</source>
               <year>2008</year>;<volume>179</volume>:<fpage>67</fpage>–<lpage>70</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C5">
            <label>5</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Lucas</surname>
                  <given-names>SM</given-names>
               </name>, <name name-style="western">
                  <surname>Stern</surname>
                  <given-names>JM</given-names>
               </name>, <name name-style="western">
                  <surname>Adibi</surname>
                  <given-names>M</given-names>
               </name>, <etal/>
               <article-title>Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques</article-title>. <source>J Urol</source>
               <year>2008</year>;<volume>179</volume>:<fpage>75</fpage>–<lpage>9</lpage>; <comment>discussion 9–80</comment>
            </citation>
         </ref>
         <ref id="AR-475441C6">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>C</given-names>
               </name>, <name name-style="western">
                  <surname>Bang</surname>
                  <given-names>JK</given-names>
               </name>, <name name-style="western">
                  <surname>Park</surname>
                  <given-names>HK</given-names>
               </name>, <etal/>
               <article-title>Factors influencing renal function reduction after partial nephrectomy</article-title>. <source>J Urol</source>
               <year>2009</year>;<volume>181</volume>:<fpage>48</fpage>–<lpage>53</lpage>; <comment>discussion 4</comment>
            </citation>
         </ref>
         <ref id="AR-475441C7">
            <label>7</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results</article-title>. <source>J Urol</source>
               <year>2010</year>;<volume>183</volume>:<fpage>1703</fpage>–<lpage>7</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C8">
            <label>8</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Iwamoto</surname>
                  <given-names>Y</given-names>
               </name>, <name name-style="western">
                  <surname>Kanda</surname>
                  <given-names>H</given-names>
               </name>, <name name-style="western">
                  <surname>Yamakado</surname>
                  <given-names>K</given-names>
               </name>, <etal/>
               <article-title>Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results</article-title>. <source>Fam Cancer</source>
               <year>2011</year>;<volume>10</volume>:<fpage>529</fpage>–<lpage>34</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C9">
            <label>9</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>SY</given-names>
               </name>, <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <etal/>
               <article-title>Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery</article-title>. <source>Acta Radiol</source>
               <year>2011</year>;<volume>52</volume>:<fpage>680</fpage>–<lpage>5</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C10">
            <label>10</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>B</given-names>
               </name>, <name name-style="western">
                  <surname>Autorino</surname>
                  <given-names>R</given-names>
               </name>, <name name-style="western">
                  <surname>Remer</surname>
                  <given-names>EM</given-names>
               </name>, <etal/>
               <article-title>Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: The Cleveland Clinic experience with 3 years follow-up</article-title>. <source>Urol Oncol</source>
               <year>2011</year>; <comment>Epub ahead of print</comment>
            </citation>
         </ref>
         <ref id="AR-475441C11">
            <label>11</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Sung</surname>
                  <given-names>HH</given-names>
               </name>, <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <etal/>
               <article-title>Comparison of percutaneous radiofrequency ablation and open partial nephrectomy for the treatment of size- and location-matched renal masses</article-title>. <source>Int J Hyperthermia</source>
               <year>2012</year>;<volume>28</volume>:<fpage>227</fpage>–<lpage>34</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C12">
            <label>12</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>HM</given-names>
               </name>. <article-title>Image-guided radiofrequency ablation of Bosniak category III or IV cystic renal tumors: initial clinical experience</article-title>. <source>Eur Radiol</source>
               <year>2008</year>;<volume>18</volume>:<fpage>1519</fpage>–<lpage>25</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C13">
            <label>13</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Miao</surname>
                  <given-names>Y</given-names>
               </name>, <name name-style="western">
                  <surname>Ni</surname>
                  <given-names>Y</given-names>
               </name>, <name name-style="western">
                  <surname>Yu</surname>
                  <given-names>J</given-names>
               </name>, <etal/>
               <article-title>A comparative study on validation of a novel cooled-wet electrode for radiofrequency liver ablation</article-title>. <source>Invest Radiol</source>
               <year>2000</year>;<volume>35</volume>:<fpage>438</fpage>–<lpage>44</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C14">
            <label>14</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Cha</surname>
                  <given-names>J</given-names>
               </name>, <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>D</given-names>
               </name>, <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>MW</given-names>
               </name>, <etal/>
               <article-title>Radiofrequency ablation zones in ex vivo bovine and in vivo porcine livers: comparison of the use of internally cooled electrodes and internally cooled wet electrodes</article-title>. <source>Cardiovasc Intervent Radiol</source>
               <year>2009</year>;<volume>32</volume>:<fpage>1235</fpage>–<lpage>40</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C15">
            <label>15</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Venkatesan</surname>
                  <given-names>AM</given-names>
               </name>, <name name-style="western">
                  <surname>Wood</surname>
                  <given-names>BJ</given-names>
               </name>, <name name-style="western">
                  <surname>Gervais</surname>
                  <given-names>DA</given-names>
               </name>. <article-title>Percutaneous ablation in the kidney</article-title>. <source>Radiology</source>
               <year>2011</year>;<volume>261</volume>:<fpage>375</fpage>–<lpage>91</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C16">
            <label>16</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Silverman</surname>
                  <given-names>SG</given-names>
               </name>, <name name-style="western">
                  <surname>Gan</surname>
                  <given-names>YU</given-names>
               </name>, <name name-style="western">
                  <surname>Mortele</surname>
                  <given-names>KJ</given-names>
               </name>, <etal/>
               <article-title>Renal masses in the adult patient: the role of percutaneous biopsy</article-title>. <source>Radiology</source>
               <year>2006</year>;<volume>240</volume>:<fpage>6</fpage>–<lpage>22</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C17">
            <label>17</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Silverman</surname>
                  <given-names>SG</given-names>
               </name>, <name name-style="western">
                  <surname>Israel</surname>
                  <given-names>GM</given-names>
               </name>, <name name-style="western">
                  <surname>Herts</surname>
                  <given-names>BR</given-names>
               </name>, <etal/>
               <article-title>Management of the incidental renal mass</article-title>. <source>Radiology</source>
               <year>2008</year>;<volume>249</volume>:<fpage>16</fpage>–<lpage>31</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C18">
            <label>18</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>EY</given-names>
               </name>. <article-title>Differentiation of Bosniak categories IIF and III cystic masses: what radiologists should know</article-title>. <source>J Comput Assist Tomogr</source>
               <year>2010</year>;<volume>34</volume>:<fpage>847</fpage>–<lpage>54</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C19">
            <label>19</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Solomon</surname>
                  <given-names>D</given-names>
               </name>, <name name-style="western">
                  <surname>Schwartz</surname>
                  <given-names>A</given-names>
               </name>. <article-title>Renal pathology in von Hippel-Lindau disease</article-title>. <source>Hum Pathol</source>
               <year>1988</year>;<volume>19</volume>:<fpage>1072</fpage>–<lpage>9</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C20">
            <label>20</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Poston</surname>
                  <given-names>CD</given-names>
               </name>, <name name-style="western">
                  <surname>Jaffe</surname>
                  <given-names>GS</given-names>
               </name>, <name name-style="western">
                  <surname>Lubensky</surname>
                  <given-names>IA</given-names>
               </name>, <etal/>
               <article-title>Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications</article-title>. <source>J Urol</source>
               <year>1995</year>;<volume>153</volume>:<fpage>22</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C21">
            <label>21</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Zagoria</surname>
                  <given-names>RJ</given-names>
               </name>, <name name-style="western">
                  <surname>Traver</surname>
                  <given-names>MA</given-names>
               </name>, <name name-style="western">
                  <surname>Werle</surname>
                  <given-names>DM</given-names>
               </name>, <etal/>
               <article-title>Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas</article-title>. <source>Am J Roentgenol</source>
               <year>2007</year>;<volume>189</volume>:<fpage>429</fpage>–<lpage>36</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C22">
            <label>22</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Lane</surname>
                  <given-names>BR</given-names>
               </name>, <name name-style="western">
                  <surname>Aydin</surname>
                  <given-names>H</given-names>
               </name>, <name name-style="western">
                  <surname>Danforth</surname>
                  <given-names>TL</given-names>
               </name>, <etal/>
               <article-title>Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid</article-title>. <source>J Urol</source>
               <year>2008</year>;<volume>180</volume>:<fpage>836</fpage>–<lpage>43</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C23">
            <label>23</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Birnbaum</surname>
                  <given-names>BA</given-names>
               </name>, <name name-style="western">
                  <surname>Hindman</surname>
                  <given-names>N</given-names>
               </name>, <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>J</given-names>
               </name>, <etal/>
               <article-title>Renal cyst pseudoenhancement: influence of multidetector CT reconstruction algorithm and scanner type in phantom model</article-title>. <source>Radiology</source>
               <year>2007</year>;<volume>244</volume>:<fpage>767</fpage>–<lpage>75</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C24">
            <label>24</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>ZJ</given-names>
               </name>, <name name-style="western">
                  <surname>Coakley</surname>
                  <given-names>FV</given-names>
               </name>, <name name-style="western">
                  <surname>Fu</surname>
                  <given-names>Y</given-names>
               </name>, <etal/>
               <article-title>Renal cyst pseudoenhancement at multidetector CT: what are the effects of number of detectors and peak tube voltage?</article-title>
               <source>Radiology</source>
               <year>2008</year>;<volume>248</volume>:<fpage>910</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C25">
            <label>25</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Bosniak</surname>
                  <given-names>MA</given-names>
               </name>, <name name-style="western">
                  <surname>Birnbaum</surname>
                  <given-names>BA</given-names>
               </name>, <name name-style="western">
                  <surname>Krinsky</surname>
                  <given-names>GA</given-names>
               </name>, <etal/>
               <article-title>Small renal parenchymal neoplasms: further observations on growth</article-title>. <source>Radiology</source>
               <year>1995</year>;<volume>197</volume>:<fpage>589</fpage>–<lpage>97</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C26">
            <label>26</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>SY</given-names>
               </name>, <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Thermal ablation in renal cell carcinoma: What affects renal function?</article-title>
               <source>Int J Hyperthermia</source>
               <year>2012</year>;<volume>28</volume>:<fpage>729</fpage>–<lpage>34</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C27">
            <label>27</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Gervais</surname>
                  <given-names>DA</given-names>
               </name>, <name name-style="western">
                  <surname>McGovern</surname>
                  <given-names>FJ</given-names>
               </name>, <name name-style="western">
                  <surname>Arellano</surname>
                  <given-names>RS</given-names>
               </name>, <etal/>
               <article-title>Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors</article-title>. <source>Am J Roentgenol</source>
               <year>2005</year>;<volume>185</volume>:<fpage>64</fpage>–<lpage>71</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C28">
            <label>28</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Herring</surname>
                  <given-names>JC</given-names>
               </name>, <name name-style="western">
                  <surname>Enquist</surname>
                  <given-names>EG</given-names>
               </name>, <name name-style="western">
                  <surname>Chernoff</surname>
                  <given-names>A</given-names>
               </name>, <etal/>
               <article-title>Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience</article-title>. <source>J Urol</source>
               <year>2001</year>;<volume>165</volume>:<fpage>777</fpage>–<lpage>81</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C29">
            <label>29</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Allaf</surname>
                  <given-names>ME</given-names>
               </name>, <name name-style="western">
                  <surname>Varkarakis</surname>
                  <given-names>IM</given-names>
               </name>, <name name-style="western">
                  <surname>Bhayani</surname>
                  <given-names>SB</given-names>
               </name>, <etal/>
               <article-title>Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation–initial observations</article-title>. <source>Radiology</source>
               <year>2005</year>;<volume>237</volume>:<fpage>366</fpage>–<lpage>70</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C30">
            <label>30</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Morrison</surname>
                  <given-names>PR</given-names>
               </name>, <name name-style="western">
                  <surname>Silverman</surname>
                  <given-names>SG</given-names>
               </name>, <name name-style="western">
                  <surname>Tuncali</surname>
                  <given-names>K</given-names>
               </name>, <etal/>
               <article-title>MRI-guided cryotherapy</article-title>. <source>J Magn Reson Imaging</source>
               <year>2008</year>;<volume>27</volume>:<fpage>410</fpage>–<lpage>20</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C31">
            <label>31</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Janzen</surname>
                  <given-names>NK</given-names>
               </name>, <name name-style="western">
                  <surname>Perry</surname>
                  <given-names>KT</given-names>
               </name>, <name name-style="western">
                  <surname>Han</surname>
                  <given-names>KR</given-names>
               </name>, <etal/>
               <article-title>The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model</article-title>. <source>J Urol</source>
               <year>2005</year>;<volume>173</volume>:<fpage>1368</fpage>–<lpage>74</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C32">
            <label>32</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Morrison</surname>
                  <given-names>PR</given-names>
               </name>, <name name-style="western">
                  <surname>Tatli</surname>
                  <given-names>S</given-names>
               </name>, <etal/>
               <article-title>Estimated effective dose of CT-guided percutaneous cryoablation of liver tumors</article-title>. <source>Eur J Radiol</source>
               <year>2012</year>;<volume>81</volume>:<fpage>1702</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C33">
            <label>33</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>HY</given-names>
               </name>, <etal/>
               <article-title>Limitation for performing ultrasound-guided radiofrequency ablation of small renal masses</article-title>. <source>Eur J Radiol</source>
               <year>2010</year>;<volume>75</volume>:<fpage>248</fpage>–<lpage>52</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C34">
            <label>34</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Kong</surname>
                  <given-names>WT</given-names>
               </name>, <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>WW</given-names>
               </name>, <name name-style="western">
                  <surname>Guo</surname>
                  <given-names>HQ</given-names>
               </name>, <etal/>
               <article-title>Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response?</article-title>
               <source>Abdom Imaging</source>
               <year>2011</year>;<volume>36</volume>:<fpage>342</fpage>–<lpage>7</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C35">
            <label>35</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>X</given-names>
               </name>, <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>W</given-names>
               </name>, <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>S</given-names>
               </name>, <etal/>
               <article-title>Improved outcome of percutaneous radiofrequency ablation in renal cell carcinoma: a retrospective study of intraoperative contrast-enhanced ultrasonography in 73 patients</article-title>. <source>Abdom Imaging</source>
               <year>2012</year>;<volume>37</volume>:<fpage>885</fpage>–<lpage>91</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C36">
            <label>36</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Mahnken</surname>
                  <given-names>AH</given-names>
               </name>, <name name-style="western">
                  <surname>Buecker</surname>
                  <given-names>A</given-names>
               </name>, <name name-style="western">
                  <surname>Spuentrup</surname>
                  <given-names>E</given-names>
               </name>, <etal/>
               <article-title>MR-guided radiofrequency ablation of hepatic malignancies at 1.5 T: initial results</article-title>. <source>J Magn Reson Imaging</source>
               <year>2004</year>;<volume>19</volume>:<fpage>342</fpage>–<lpage>8</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C37">
            <label>37</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Will</surname>
                  <given-names>K</given-names>
               </name>, <name name-style="western">
                  <surname>Krug</surname>
                  <given-names>J</given-names>
               </name>, <name name-style="western">
                  <surname>Jungnickel</surname>
                  <given-names>K</given-names>
               </name>, <etal/>
               <article-title>MR-compatible RF ablation system for online treatment monitoring using MR thermometry</article-title>. <source>Conf Proc IEEE Eng Med Biol Soc</source>
               <year>2010</year>;<volume>2010</volume>:<fpage>1601</fpage>–<lpage>4</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C38">
            <label>38</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>McGahan</surname>
                  <given-names>JP</given-names>
               </name>, <name name-style="western">
                  <surname>Loh</surname>
                  <given-names>S</given-names>
               </name>, <name name-style="western">
                  <surname>Fitzgerald</surname>
                  <given-names>E</given-names>
               </name>, <etal/>
               <article-title>Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation</article-title>. <source>Am J Roentgenol</source>
               <year>2011</year>;<volume>197</volume>:<fpage>1244</fpage>–<lpage>50</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C39">
            <label>39</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Ukimura</surname>
                  <given-names>O</given-names>
               </name>, <name name-style="western">
                  <surname>Mitterberger</surname>
                  <given-names>M</given-names>
               </name>, <name name-style="western">
                  <surname>Okihara</surname>
                  <given-names>K</given-names>
               </name>, <etal/>
               <article-title>Real-time virtual ultrasonographic radiofrequency ablation of renal cell carcinoma</article-title>. <source>BJU Int</source>
               <year>2008</year>;<volume>101</volume>:<fpage>707</fpage>–<lpage>11</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C40">
            <label>40</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Varro</surname>
                  <given-names>Z</given-names>
               </name>, <name name-style="western">
                  <surname>Locklin</surname>
                  <given-names>JK</given-names>
               </name>, <name name-style="western">
                  <surname>Wood</surname>
                  <given-names>BJ</given-names>
               </name>. <article-title>Laser navigation for radiofrequency ablation</article-title>. <source>Cardiovasc Intervent Radiol</source>
               <year>2004</year>;<volume>27</volume>:<fpage>512</fpage>–<lpage>5</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C41">
            <label>41</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods</article-title>. <source>Eur Radiol</source>
               <year>2009</year>;<volume>19</volume>:<fpage>2180</fpage>–<lpage>90</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C42">
            <label>42</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Using an electrode as a lever to increase the distance between renal cell carcinoma and bowel during CT-guided radiofrequency ablation</article-title>. <source>Eur Radiol</source>
               <year>2008</year>;<volume>18</volume>:<fpage>743</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C43">
            <label>43</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Boss</surname>
                  <given-names>A</given-names>
               </name>, <name name-style="western">
                  <surname>Clasen</surname>
                  <given-names>S</given-names>
               </name>, <name name-style="western">
                  <surname>Kuczyk</surname>
                  <given-names>M</given-names>
               </name>, <etal/>
               <article-title>Thermal damage of the genitofemoral nerve due to radiofrequency ablation of renal cell carcinoma: a potentially avoidable complication</article-title>. <source>Am J Roentgenol</source>
               <year>2005</year>;<volume>185</volume>:<fpage>1627</fpage>–<lpage>31</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C44">
            <label>44</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Farrell</surname>
                  <given-names>MA</given-names>
               </name>, <name name-style="western">
                  <surname>Charboneau</surname>
                  <given-names>JW</given-names>
               </name>, <name name-style="western">
                  <surname>Callstrom</surname>
                  <given-names>MR</given-names>
               </name>, <etal/>
               <article-title>Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation</article-title>. <source>Am J Roentgenol</source>
               <year>2003</year>;<volume>181</volume>:<fpage>1315</fpage>–<lpage>7</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C45">
            <label>45</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Kam</surname>
                  <given-names>AW</given-names>
               </name>, <name name-style="western">
                  <surname>Littrup</surname>
                  <given-names>PJ</given-names>
               </name>, <name name-style="western">
                  <surname>Walther</surname>
                  <given-names>MM</given-names>
               </name>, <etal/>
               <article-title>Thermal protection during percutaneous thermal ablation of renal cell carcinoma</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2004</year>;<volume>15</volume>:<fpage>753</fpage>–<lpage>8</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C46">
            <label>46</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Maturen</surname>
                  <given-names>KE</given-names>
               </name>, <name name-style="western">
                  <surname>Nghiem</surname>
                  <given-names>HV</given-names>
               </name>, <name name-style="western">
                  <surname>Caoili</surname>
                  <given-names>EM</given-names>
               </name>, <etal/>
               <article-title>Renal mass core biopsy: accuracy and impact on clinical management</article-title>. <source>Am J Roentgenol</source>
               <year>2007</year>;<volume>188</volume>:<fpage>563</fpage>–<lpage>70</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C47">
            <label>47</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>R</given-names>
               </name>, <name name-style="western">
                  <surname>Wolf</surname>
                  <given-names>JS</given-names>
                  <suffix>Jr</suffix>
               </name>, <name name-style="western">
                  <surname>Wood</surname>
                  <given-names>DP</given-names>
                  <suffix>Jr</suffix>
               </name>, <etal/>
               <article-title>Accuracy of percutaneous core biopsy in management of small renal masses</article-title>. <source>Urology</source>
               <year>2009</year>;<volume>73</volume>:<fpage>586</fpage>–<lpage>90</lpage>; <comment>discussion 90–1</comment>
            </citation>
         </ref>
         <ref id="AR-475441C48">
            <label>48</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>SH</given-names>
               </name>, <name name-style="western">
                  <surname>Byun</surname>
                  <given-names>JY</given-names>
               </name>, <etal/>
               <article-title>CT-guided instillation of 5% dextrose in water into the anterior pararenal space before renal radiofrequency ablation in a porcine model: positive and negative effects</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2007</year>;<volume>18</volume>:<fpage>1561</fpage>–<lpage>9</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C49">
            <label>49</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Wah</surname>
                  <given-names>TM</given-names>
               </name>, <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>P</given-names>
               </name>, <name name-style="western">
                  <surname>Irving</surname>
                  <given-names>HC</given-names>
               </name>, <etal/>
               <article-title>Radiofrequency ablation of a central renal tumor: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2005</year>;<volume>16</volume>:<fpage>1551</fpage>–<lpage>5</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C50">
            <label>50</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Cantwell</surname>
                  <given-names>CP</given-names>
               </name>, <name name-style="western">
                  <surname>Wah</surname>
                  <given-names>TM</given-names>
               </name>, <name name-style="western">
                  <surname>Gervais</surname>
                  <given-names>DA</given-names>
               </name>, <etal/>
               <article-title>Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2008</year>;<volume>19</volume>:<fpage>1034</fpage>–<lpage>40</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C51">
            <label>51</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Mechanical ureteral perforation by a radiofrequency electrode during ablation of a renal tumor</article-title>. <source>Cardiovasc Intervent Radiol</source>
               <year>2009</year>;<volume>32</volume>:<fpage>1317</fpage>–<lpage>9</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C52">
            <label>52</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Goldberg</surname>
                  <given-names>SN</given-names>
               </name>, <name name-style="western">
                  <surname>Grassi</surname>
                  <given-names>CJ</given-names>
               </name>, <name name-style="western">
                  <surname>Cardella</surname>
                  <given-names>JF</given-names>
               </name>, <etal/>
               <article-title>Image-guided tumor ablation: standardization of terminology and reporting criteria</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2005</year>;<volume>16</volume>:<fpage>765</fpage>–<lpage>78</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C53">
            <label>53</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Steinbach</surname>
                  <given-names>F</given-names>
               </name>, <name name-style="western">
                  <surname>Novick</surname>
                  <given-names>AC</given-names>
               </name>, <name name-style="western">
                  <surname>Zincke</surname>
                  <given-names>H</given-names>
               </name>, <etal/>
               <article-title>Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study</article-title>. <source>J Urol</source>
               <year>1995</year>;<volume>153</volume>:<fpage>1812</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C54">
            <label>54</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Meloni</surname>
                  <given-names>MF</given-names>
               </name>, <name name-style="western">
                  <surname>Goldberg</surname>
                  <given-names>SN</given-names>
               </name>, <name name-style="western">
                  <surname>Moser</surname>
                  <given-names>V</given-names>
               </name>, <etal/>
               <article-title>Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma</article-title>. <source>Eur J Ultrasound</source>
               <year>2002</year>;<volume>15</volume>:<fpage>73</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C55">
            <label>55</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <name name-style="western">
                  <surname>Moo</surname>
                  <given-names>HL</given-names>
               </name>. <article-title>Arteriovenous fistula after radiofrequency ablation of a renal tumor located within the renal sinus</article-title>. <source>J Vasc Interv Radiol</source>
               <year>2007</year>;<volume>18</volume>:<fpage>1183</fpage>–<lpage>5</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C56">
            <label>56</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>. <article-title>Prognostic factors influencing the development of an iatrogenic pneumothorax for computed tomography-guided radiofrequency ablation of upper renal tumor</article-title>. <source>Acta Radiol</source>
               <year>2008</year>;<volume>49</volume>:<fpage>1200</fpage>–<lpage>6</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C57">
            <label>57</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Ahrar</surname>
                  <given-names>K</given-names>
               </name>, <name name-style="western">
                  <surname>Matin</surname>
                  <given-names>S</given-names>
               </name>, <name name-style="western">
                  <surname>Wallace</surname>
                  <given-names>MJ</given-names>
               </name>, <etal/>
               <article-title>Percutaneous transthoracic radiofrequency ablation of renal tumors using an iatrogenic pneumothorax</article-title>. <source>Am J Roentgenol</source>
               <year>2005</year>;<volume>185</volume>:<fpage>86</fpage>–<lpage>8</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C58">
            <label>58</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
               </name>, <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CK</given-names>
               </name>, <name name-style="western">
                  <surname>Lim</surname>
                  <given-names>HK</given-names>
               </name>. <article-title>Renal infarction resulting from segmental arterial injury during radiofrequency ablation of renal tumor in patient with a single kidney</article-title>. <source>Urology</source>
               <year>2009</year>;<volume>73</volume>:<fpage>442</fpage>
               <comment>e9–11</comment>
            </citation>
         </ref>
         <ref id="AR-475441C59">
            <label>59</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Joly</surname>
                  <given-names>D</given-names>
               </name>, <name name-style="western">
                  <surname>Mejean</surname>
                  <given-names>A</given-names>
               </name>, <name name-style="western">
                  <surname>Correas</surname>
                  <given-names>JM</given-names>
               </name>, <etal/>
               <article-title>Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease</article-title>. <source>J Urol</source>
               <year>2011</year>;<volume>185</volume>:<fpage>2056</fpage>–<lpage>60</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C60">
            <label>60</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Altunrende</surname>
                  <given-names>F</given-names>
               </name>, <name name-style="western">
                  <surname>Autorino</surname>
                  <given-names>R</given-names>
               </name>, <name name-style="western">
                  <surname>Hillyer</surname>
                  <given-names>S</given-names>
               </name>, <etal/>
               <article-title>Image guided percutaneous probe ablation for renal tumors in 65 solitary kidneys: functional and oncological outcomes</article-title>. <source>J Urol</source>
               <year>2011</year>;<volume>186</volume>:<fpage>35</fpage>–<lpage>41</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C61">
            <label>61</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Bourne</surname>
                  <given-names>AE</given-names>
               </name>, <name name-style="western">
                  <surname>Kramer</surname>
                  <given-names>BA</given-names>
               </name>, <name name-style="western">
                  <surname>Steiner</surname>
                  <given-names>HL</given-names>
               </name>, <etal/>
               <article-title>Renal insufficiency is not a contraindication for cryoablation of small renal masses</article-title>. <source>J Endourol</source>
               <year>2009</year>;<volume>23</volume>:<fpage>1195</fpage>–<lpage>8</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C62">
            <label>62</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Mues</surname>
                  <given-names>AC</given-names>
               </name>, <name name-style="western">
                  <surname>Landman</surname>
                  <given-names>J</given-names>
               </name>. <article-title>Results of kidney tumor cryoablation: renal function preservation and oncologic efficacy</article-title>. <source>World J Urol</source>
               <year>2010</year>;<volume>28</volume>:<fpage>565</fpage>–<lpage>70</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C63">
            <label>63</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Pettus</surname>
                  <given-names>JA</given-names>
               </name>, <name name-style="western">
                  <surname>Werle</surname>
                  <given-names>DM</given-names>
               </name>, <name name-style="western">
                  <surname>Saunders</surname>
                  <given-names>W</given-names>
               </name>, <etal/>
               <article-title>Percutaneous radiofrequency ablation does not affect glomerular filtration rate</article-title>. <source>J Endourol</source>
               <year>2010</year>;<volume>24</volume>:<fpage>1687</fpage>–<lpage>91</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C64">
            <label>64</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Weisbrod</surname>
                  <given-names>AJ</given-names>
               </name>, <name name-style="western">
                  <surname>Atwell</surname>
                  <given-names>TD</given-names>
               </name>, <name name-style="western">
                  <surname>Frank</surname>
                  <given-names>I</given-names>
               </name>, <etal/>
               <article-title>Percutaneous cryoablation of masses in a solitary kidney</article-title>. <source>Am J Roentgenol</source>
               <year>2010</year>;<volume>194</volume>:<fpage>1620</fpage>–<lpage>5</lpage>
            </citation>
         </ref>
         <ref id="AR-475441C65">
            <label>65</label>
            <citation citation-type="journal" xlink:type="simple">
               <name name-style="western">
                  <surname>Tsalafoutas</surname>
                  <given-names>IA</given-names>
               </name>, <name name-style="western">
                  <surname>Tsapaki</surname>
                  <given-names>V</given-names>
               </name>, <name name-style="western">
                  <surname>Triantopoulou</surname>
                  <given-names>C</given-names>
               </name>, <etal/>
               <article-title>CT-guided interventional procedures without CT fluoroscopy assistance: patient effective dose and absorbed dose considerations</article-title>. <source>Am J Roentgenol</source>
               <year>2007</year>;<volume>188</volume>:<fpage>1479</fpage>–<lpage>84</lpage>
            </citation>
         </ref>
      </ref-list>
   </back>
</article>